Evidence map›Paper›PMID 41473752›Full record

ArticleNeuro-oncology advances

Intracerebral hemorrhage risk in glioma patients taking direct oral anticoagulants as compared with low molecular weight heparin.

Radhika S Amin, Scott Cameron, Matthew M Grabowski, Justin D Lathia, Mina Lobbous, Mark G Malkin, David M Peereboom, Anthony R Sloan, Glen H J Stevens, Alejandro Torres-Trejo and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Radhika S AminSchool of Medicine, Case Western Reserve University, Cleveland, Ohio.ORCID https://orcid.org/0009-0004-8012-6929
Scott CameronCleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio.
Matthew M GrabowskiCleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio.
Justin D LathiaCleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio.ORCID https://orcid.org/0000-0003-3168-7290
Mina LobbousCleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio.
Mark G MalkinCleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio.
David M PeereboomCleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio.
Anthony R SloanCleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio.ORCID https://orcid.org/0000-0001-7994-3316
Glen H J StevensCleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio.
Alejandro Torres-TrejoCleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio.
Surabhi RanjanDepartment of Neurosurgery, Cleveland Clinic Florida, Weston, Florida.
Andrew DhawanCleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio.ORCID https://orcid.org/0000-0002-5027-1277

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abstract: BackgroundGlioma patients may require long-term anticoagulation for comorbidities, including arrhythmias or venous thromboembolism (VTE). While direct oral anticoagulants (DOACs) have demonstrated safety in general cancer populations, safety data for glioma patients remains limited. The aim of this study was to assess intracerebral hemorrhage (ICH) risk with DOAC compared to low molecular weight heparin (LMWH) in glioma patients. Methods: We reviewed adult patients with primary glioma who received DOAC and/or LMWH for at least 10 days between 2008 and 2023 across Cleveland Clinic Health System hospitals. ICH rates and severity were compared between treatment groups. Results: Among 277 patients (147 DOAC, 130 LMWH), median time from tumor diagnosis to first VTE was 70 days, with 32% experiencing VTE within six months of glioma diagnosis. Of these, 74% had glioblastoma. No statistically significant difference in ICH risk was found between DOAC and LMWH groups ( Conclusions: This observational study suggests DOACs are relatively safe in glioma patients given the low ICH risk. While most ICH events occurred in glioblastoma patients, no significant difference in risk was found across tumor grades. Prospective studies will establish anticoagulation risks in this population.

Indexed as

direct oral anticoagulation | glioma | intracerebral hemorrhage | low molecular weight heparin | venous thromboembolism

Identifiers

PMID41473752
PMCPMC12746604

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.